IPG Photonics bids €300m for Lumibird Medical to build laser platform
IPG Photonics has entered into a binding offer to acquire Lumibird Medical, the French medical laser specialist, for a base price of €300 million in cash on a cash-free, debt-free basis. The deal includes a contingent earnout of up to €50 million tied to 2026 and 2027 performance targets, bringing the potential total consideration to €350 million. IPG intends to fund the transaction entirely from its existing cash reserves.
The acquisition is expected to close in the fourth quarter of 2026, subject to the completion of an information and consultation process with Lumibird Medical's works council under French labour law and the satisfaction of customary regulatory conditions. The parties will enter a definitive purchase agreement once that process concludes.
The deal
Lumibird Medical, headquartered in France, is a global supplier of diagnostic and therapeutic laser systems for ophthalmology, addressing conditions such as cataracts, glaucoma, dry eye and age-related macular degeneration. Its commercial portfolio is built around the Quantel Medical, Ellex and Optotek Medical brands. For the fiscal year ended 31 December 2025, the company reported revenue of €112.2 million and EBITDA of €24.1 million, representing an EBITDA margin of 21.5 per cent.
IPG Photonics, listed on NASDAQ and best known as a maker of fibre lasers for industrial applications, has been building a medical laser segment through its Advanced Solutions portfolio, with an existing position in urology lasers. The company says the Lumibird Medical acquisition adds approximately $1 billion to its serviceable addressable market and is expected to be accretive to gross margin, EBITDA and adjusted earnings per share from close.
Mark Gitin, chief executive of IPG Photonics, said that Lumibird Medical's ophthalmology leadership "complements our strength in urology, which will create a scaled medical platform with opportunities to accelerate innovation, broaden our commercial reach and deliver differentiated solutions for physicians and patients." Jean-Marc Gendre, CEO of Lumibird Medical, said the combination would give the business access to IPG's scale in lasers and photonics.
Market context
The ophthalmic laser market sits at a structurally attractive intersection of ageing demographics and non-discretionary clinical need. Conditions such as age-related macular degeneration and glaucoma require ongoing intervention, giving suppliers relatively predictable, recurring revenue streams that are less exposed to consumer sentiment than elective medical device categories.
Lumibird Medical competes in a market that also includes the dedicated ophthalmic divisions of larger medical-technology groups, as well as specialist players focused on retinal and anterior-segment laser systems. For IPG, the move represents a meaningful step away from its industrial laser heritage and deeper into regulated healthcare, a transition that carries integration risk but also insulates a portion of revenues from cyclical manufacturing markets.
Regulatory approvals required for the transaction are not expected to be onerous given that the two companies operate in complementary rather than overlapping product categories, though IPG's release notes the standard caveat that closing cannot be guaranteed on the anticipated timeline. Investors will be watching for any revision to the earnout structure and for early indications of how the combined commercial organisations will be integrated across IPG's existing urology sales channels.